Site search

Clear filter
2897 results for '' found
BiVACOR® Total Artificial Heart Clinical Feasibility Study (ACTRN12624001379505)
BiVACOR® Total Artificial Heart Clinical Feasibility Study (ACTRN12624001379505)
/
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) (NCT06241573)
/
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With
/
BHV3000-406: A Phase 4, Randomized, Doubleblind Placebo-Controlled, Efficacy and TolerabilityTrial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (NCT05509
/
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Pati
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Pati
/
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabin
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabin
/
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marg
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marg
/
An Open-label, Multi-centre, Long-term Extension Study of Zanubrutinib (BGB-3111) in patients with B-cell Malignancies (BGB-3111-LTE1) (NCT04170283)
An Open-label, Multi-centre, Long-term Extension Study of Zanubrutinib (BGB-3111) in patients with B-cell Malignancies (BGB-3111-LTE1) (NCT04170283)
/
A Phase 1, Open-Label, Dose Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein Degrader BGB-16673 in Patients with B Cell Malignancies (BGB-16673-101) (NCT05006716)
A Phase 1, Open-Label, Dose Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein Degrader BGB-16673 in Patients with B Cell Malignancies (BGB-16673-101) (NCT05006716)
/
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patie
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patie
/
59 60 61 62 63